SecBot SecBot
8-K ·Filed Aug 5, 2026

KYMR

Kymera Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed3mo ago SEC0001193125-26-333834
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The accelerated KT-621 Phase 2b readout to year-end 2026 is the primary catalyst. Traders should monitor the data release closely; positive results could drive a re-rating given the large TAM in Type 2 inflammation. Partnership milestones provide near-term cash but pipeline data is the key value driver. Watch for KT-579 Phase 1 data in Q4 2026.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$105.48
T+0 close · Aug 5, 2026 · via day close
Latest settled
+14.50%
T+60 · $120.78
Vs SPY
+14.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $105.48entry
  2. T+1 · 3mo ago +0.88%α +1.04% · $106.41
  3. T+5 · 3mo ago +8.11%α +7.76% · $114.03
  4. T+20 · 3mo ago +12.47%α +13.07% · $118.63
  5. T+60 · 19d ago +14.50%α +14.31% · $120.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kymera Therapeutics reported Q2 2026 collaboration revenue of $65.0M (well above $32.8M consensus) and EPS of -$0.62 (beating -$0.74 consensus). The key catalyst is the completion of enrollment in the KT-621 Phase 2b AD trial nearly six months ahead of schedule, pulling forward topline data to year-end 2026, along with $65M in milestone payments from Gilead and Sanofi. The company ended the quarter with $1.5B cash, providing runway into 2029.

Key Financial Metrics

EPS
−$0.62
est −$0.74 · +16.2%
Revenue
$65.0M
est $32.8M · +98.2% · +465.0% YoY
Rating
beat

Key Facts

  • Collaboration revenue $65.0M vs consensus $32.8M (beat), driven by $45M Gilead option and $20M Sanofi milestone
  • EPS -$0.62 vs consensus -$0.74 (16.0% beat)
  • KT-621 BROADEN2 Phase 2b AD trial enrollment completed ~6 months ahead of schedule; data readout accelerated to year-end 2026
  • KT-621 Phase 3 trials in AD planned to initiate by mid-2027
  • KT-579 (IRF5) Phase 1 data expected in Q4 2026; Phase 1b lupus trial planned
  • Sanofi initiated Phase 1 for KT-485 (IRAK4), triggering a $20M milestone
  • Cash position: $1.5B as of June 30, 2026, providing runway into 2029
  • Net loss improved to $61.2M (from $76.6M in Q2 2025)
  • New CMO appointed (Terence Rooney) and new Chairman (Felix J. Baker)

Financial Impact

Significant revenue beat driven by $65M in non-recurring milestones; net loss improved 20% YoY; cash slightly down but ample runway

collaboration revenuenet losscash position

Risk Factors

  • KT-621 Phase 2b data may fail to meet efficacy or safety endpoints, resetting timelines
  • Non-recurring milestone revenue creates lumpy financials; operating expenses continue to rise (R&D +52% YoY)
  • Execution risk on Phase 3 initiation and multiple parallel trials
  • Competition from approved biologics and other oral agents in development

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-333834
Document: kymr-20260805.htm0001193125-26-333834
Document: 0001193125-26-333834-index-headers.html0001193125-26-333834
Document: 0001193125-26-333834-index.html0001193125-26-333834
Document: 0001193125-26-333834.txt0001193125-26-333834
8-K Data (Synthetic)0001193125-26-333834

Track record

37 reports on KYMR

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 8 of 13 went positive at some point.

Filters
  1. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
  2. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  3. Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
  4. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
  5. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Viewing Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
  9. Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens Wed (9h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026